Bristol Myers Squibb plans $2 billion in cost cuts by 2027, issues weak guidance


 Bristol Myers Squibb on Thursday said it  King88bet Login  will slash $2 billion in costs by the end of 2027, expanding its ongoing cost-savings usaha to chart a path toward long-term growth.


Bristol Myers said savings will be driven by organizational changes and usahas to streamline operations, and will allow the company to invest in new science and drug brands expected to deliver growth.


The pharmaceutical giant still plans to cut $1.5 billion in costs by the end of 2025 and funnel that money into drug development. It first announced those cuts in April, and expanded on them with Thursday's announcement.


The company is preparing to offset the King88bet Slot   loss in revenue from top-selling treatments slated to lose exclusivity on the pasar, including its blockbuster blood thinner Eliquis and cancer immunotherapy Opdivo.


Also on Thursday, Bristol Myers Squibb issued full-year 2025 guidance that fell short of Wall Street's expectations, as some of the company's older drugs face competition from cheaper generics. That includes four drugs for different cancers: Revlimid, Pomalyst, Sprycel and Abraxane.


Bristol Myers expects revenue to come in around $45.5 billion, which is below the $47.36 billion that analysts surveyed by LSEG were expecting.


The company's revenue guidance also  King88bet Tergacor   reflects an approximately $500 million expected negative impact from foreign exchange.


The drugmaker expects adjusted earnings per sharing of between $6.55 and $6.85. Analysts surveyed by LSEG expected adjusted earnings of $6.92 per sharing.


Despite that outlook, Bristol Myers reported fourth-quarter revenue and adjusted earnings that blew past expectations, boosted by Eliquis and the company's so-called growth portfolio of drugs.


Here is what Bristol Myers reported for the fourth quarter compared with what Wall Street was expecting, based on a survei of analysts by LSEG:


Earnings per sharing: $1.67 adjusted versus. $1.46 expected

Revenue: $12.34 billion versus. $11.57 billion expected

Bristol Myers posted net penghasilan of $72 million, or 4 cents per sharing, for the fourth quarter. That compares with net penghasilan of $1.8 billion, or 87 cents per sharing, for the year-earlier period.


Excluding certain items, it reported adjusted earnings per sharing of $1.67 for the quarter.


The pharmaceutical giant's revenue rose 8% from the same period a year ago to $12.34 billion.


Eliquis booked $3.2 billion in sales for the quarter, up 11% from the year-ago period. That is above the $3.03 billion that analysts were expecting, according to estimates compiled by StreetAccount.


The blood thinner, which Bristol Myers shares with Pfizer

, is expected to lose pasar exclusivity by 2028.


Sales of Eliquis could also take a hit in 2026, when a new negotiated price for the drug goes into efek for certain Medicare patients following negotiations with the federasi government. Those price talks are a key provision of the Inflation Reduction Act.


The second round of negotiations sasarans 15 additional drugs and will set new prices that will go into efek in 2028. That includes Pomalyst, which is used to treat a blood cancer called multiple myeloma and a cancer that develops in people with HIV.

Postingan populer dari blog ini

Henrot has actually an individual link towards a minimum

Why is cancer called cancer?

along with women's as well as girls' organizations expanding particularly